Related Experiment Video

Updated: Jul 11, 2026

Effective Isolation of Functional Islets from Neonatal Mouse Pancreas
07:04

Effective Isolation of Functional Islets from Neonatal Mouse Pancreas

Published on: January 6, 2017

Insulin pump therapy in neonatal diabetes

Nadia Tubiana-Rufi1

  • 1Department of Endocrinology and Diabetology, Robert Debré Hospital, AP-HP, Paris , France.

Endocrine Development
|October 10, 2007
PubMed

Insights

Continuous subcutaneous insulin infusion (CSII) offers a safe and accurate method for managing neonatal diabetes mellitus. This approach allows for precise insulin delivery, closely matching infant feeding needs and improving glycemic control with fewer complications.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Metabolic Disorders

Background:

  • Neonatal diabetes mellitus is a rare condition characterized by hyperglycemia in infants within the first six weeks of life.
  • Managing insulin therapy in newborns presents significant challenges due to difficulties in precise insulin delivery and the risk of hypoglycemia.
  • Limited data exist on effective insulin delivery methods for neonatal diabetes, necessitating further investigation into advanced therapeutic approaches.

Purpose of the Study:

  • To evaluate the safety, efficacy, and manageability of continuous subcutaneous insulin infusion (CSII) in infants with neonatal diabetes mellitus.
  • To compare CSII with traditional insulin injections for managing very small insulin doses and complex feeding regimens in neonates.
  • To assess the long-term outcomes and tolerability of CSII in infants requiring insulin therapy for over 15 days.

Main Methods:

  • Retrospective analysis of 18 years of data on 17 infants with neonatal diabetes requiring insulin therapy for more than 15 days.
  • Implementation of CSII with specific protocols for insulin dilution (5-10 U/ml) to manage microdoses (e.g., 0.20 U bolus, 0.02 U/h basal).
  • Adaptation of CSII basal and bolus rates to accommodate continuous enteral/parenteral feeding and intermittent bottle feeding schedules.

Main Results:

  • CSII enabled precise adaptation of insulin delivery to match infant feeding regimens, including basal rates for continuous feeding and preprandial boluses for intermittent feeds.
  • Accurate administration of very small insulin doses was achieved through insulin dilution and CSII, surpassing the precision of traditional syringes.
  • CSII demonstrated efficient blood glucose control with a reduced incidence of hypoglycemia compared to injections, and infants tolerated infusion lines well without adverse effects.

Conclusions:

  • Continuous subcutaneous insulin infusion (CSII) is a safe, physiological, and accurate method for managing neonatal diabetes during the neonatal period.
  • CSII simplifies insulin therapy management by allowing precise adjustments to insulin delivery, facilitating better glycemic control and matching infant nutritional needs.
  • Under experienced team supervision, CSII is a superior alternative to injections for infants requiring long-term insulin therapy for neonatal diabetes.

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...